Skip to main content

Galectin Therapeutics Inc

GALT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001133416

In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Galectin Therapeutics Inc changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of GALT: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders7570−5
Shares7.92M7.29M−627.4K (−7.9%)
Value$25.3M$28.2M+$2.90M (+11.4%)

New holders (9)

Institutions that held Galectin Therapeutics Inc at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to GALT in Q3 2021
InstitutionSharesValue% of portfolio
Keybank National Association100,000$388.0K0.00%
Capstone Investment Advisors, LLC42,260$164.0K0.00%
Citadel Advisors LLC24,432$95.0K0.00%
Raymond James & Associates13,096$51.0K0.00%
Commonwealth Equity Services, LLC11,902$46.0K0.00%
Buckingham Strategic Wealth, LLC10,734$42.0K0.00%
Cutler Group LP3,500$13.0K0.00%
Jacobi Capital Management LLC225$1.00K0.00%
Reilly Financial Advisors, LLC150––

Sold out (14)

Institutions that held Galectin Therapeutics Inc at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of GALT in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Tibra Equities Europe Ltd98,700$316.0K
Marshall Wace, LLP47,509$152.0K
ExodusPoint Capital Management, LP42,042$135.0K
D. E. Shaw & Co., Inc.20,607$66.0K
LMR Partners LLP19,285$62.0K
Susquehanna Fundamental Investments, LLC15,600$50.0K
XTX Topco Ltd12,419$40.0K
Jane Street Group, LLC11,133$36.0K
Boothbay Fund Management, LLC10,965$35.0K
Pinz Capital Management, LP6,300$20.0K
O'Shaughnessy Asset Management, LLC5,655$18.0K
Citigroup Inc557$2.00K
New York State Common Retirement Fund259$1.00K
Captrust Financial Advisors213$1.00K